Global Influenza Drugs and Vaccines Market by Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marbo

Comments · 292 Views

The global Influenza Drugs and Vaccines Market is mainly driven by the annual epidemic outbreak in developed countries such as the US and flu outbreaks in various regions worldwide.

The global Influenza Drugs and Vaccines Market is mainly driven by the annual epidemic outbreak in developed countries such as the US and flu outbreaks in various regions worldwide.

Influenza is a contagious respiratory viral infection that can cause a range of symptoms, including fever, cough, runny nose, congestion, fatigue, and muscle aches. The disease affects a significant portion of the US population each year, with 5% to 20% of people being affected annually, and resulting in approximately 36,000 deaths due to complications, according to the Centers for Disease Control and Prevention (CDC). In 2019, there were 9.7 million reported cases of influenza in the United States alone. Vaccines and drugs are the most effective ways to prevent influenza.

Get a free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/3592

The market includes the application of seasonal vaccines. Rising awareness of the serious impacts of influenza, particularly on high-risk populations like pregnant women, the elderly, and people with weak immune systems, is a significant driver of market growth. The virus's genetic mutation nature has resulted in the development of new therapeutics and the introduction of new influenza medications, which is expected to fuel the influenza drugs and vaccines market.

The market has been classified into product, distribution channel, and region. The product category includes zanamivir, peramivir, amantadine, oseltamivir, rimantadine, inosine, and others. Oseltamivir held the most significant revenue share of 48.8% in 2019, owing to its increasing use in the treatment of flu triggered by the H1N1 virus and prophylaxis.

The market is divided into hospitals, clinics, pharmacies, and others, and the pharmacies segment held dominance in 2019. Growth in this segment is expected to remain steady due to the increasing incidence and prevalence of flu worldwide, coupled with the proliferation of pharmacy stores worldwide.

Favorable government policies for the treatment and prevention of influenza have been issued in developed regions, driving the growth of the influenza drugs and vaccines market. The Asia Pacific market is expected to grow at a high CAGR of 1.8% during the forecast period due to the availability of low-cost treatment and better healthcare facilities. The major restraining factors affecting the influenza drugs and vaccines market are the patent expiry of key drugs and entry of generics and the side effects of anti-influenza drug therapy.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/3592

The global influenza drugs and vaccines market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East Africa. In 2016, North America and Europe accounted for the largest share of the influenza drugs and vaccines market, followed by Asia Pacific, Latin America, and Middle East Africa. The US dominated the market in North America, while China and India were major contributors to the growth of the market in Asia Pacific.

The key players operating in the global influenza drugs and vaccines market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., and Mylan, Inc.

In conclusion, the global influenza drugs and vaccines market is expected to grow due to rising awareness of the serious impacts of influenza, increasing incidence and prevalence of flu worldwide, and favorable government policies. The Asia Pacific market is expected to be the most lucrative during the forecast period due to the availability of low-cost treatment and better healthcare facilities. However, patent expiry of key drugs and entry of generics and side effects of anti-influenza drug therapy are major restraining factors affecting the market.

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/3592

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Comments